Safety and Efficacy of Adalimumab in Noninfectious Uveitis

Synopsis The efficacy of adalimumab in managing active uveitis is demonstrated in 2 randomized, double-masked, placebo-controlled trials (VISUAL I & VISUAL II). The present study aims to evaluate the safety and efficacy of adalimumab in patients with noninfectious intermediate, posterior, or pan-uveitis (VISUAL III). This week’s “ MED FACT ” discusses a clinical trial from Ophthalmology, “ Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III ”. Authors: EB.

Suhler et. al. Key Takeaways Patients with inactive uveitis sustained quiescence without an increase in systemic corticosteroid dose. Objective: To evaluate the safety and efficacy of extended adalimumab treatment in patients with non-infectious intermediate, posterior, or pan-uveitis who successfully completed the VISUAL I or VISUAL II trials without treatment failure or…